Physician profile
Michael G Wells
NPI 1033181367
$5,413.84
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $1,267 · 2021: $2,088 · 2022: $754 · 2023: $150 · 2024: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $630.24 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $605.51 | 2019-2022 | |
| Novo Nordisk INC | $505.76 | 2019-2022 | |
| Lilly USA, LLC | $487.14 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.31 | 2019-2023 | Jardiance |
| Pfizer INC. | $445.06 | 2019-2022 | |
| Glaxosmithkline, LLC. | $292.55 | 2019-2022 | |
| Amgen INC. | $256.37 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $172.80 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.57 | 2019-2021 | |
| Astellas Pharma US INC | $149.45 | 2019-2021 | |
| Eisai INC. | $135.43 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $130.07 | 2023 | Gemtesa |
| Nevro Corp. | $128.55 | 2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $121.81 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $107.86 | 2019-2020 | |
| Abbott Laboratories | $107.69 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $88.36 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $77.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.07 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.24 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.95 | 2022 | |
| Esperion Therapeutics, INC. | $33.62 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $26.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.18 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.92 | 2019-2022 | |
| Mylan Specialty L.P. | $22.42 | 2019-2020 | |
| Allergan, INC. | $17.80 | 2021 | |
| Optos, INC. | $16.67 | 2020 | |
| Genentech USA, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.